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and Os(II)-Based Complexes as 
Photosensitizers
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and Mark Roufaiel
Abstract
Photodynamic therapy (PDT) is an approved procedure using a photosensi-
tizer (PS) activated by light to selectively destroy malignant/premalignant cells. 
Transition metal complexes, such as Ru(II)- and Os(II)-based PSs (Theralase 
Technologies Inc., Ontario. Canada), are activated in a wide range of wavelengths, 
are resistant to photobleaching and have a high singlet oxygen quantum yield and 
ability to produce cytotoxic reactive oxygen species (ROS). Their design allows 
fine-tuning of the photophysical and photochemical properties. They demonstrate 
Type I and II photoreactions, and some are activated in hypoxia. High PDT potency 
and activation under NIR light and even X-ray may provide an advantage over the 
approved PSs. Their ability to associate with transferrin (Tf) as an endogenous 
delivery system increases photobleaching resistance, ROS production, selective 
cellular uptake, and PDT efficacy in combination with a decreased systemic toxic-
ity. This makes these PSs attractive for systemic therapy of recurrent/progressive 
cancers. Their PDT efficacy has been demonstrated in various in vitro and in vivo 
clinically relevant models. The unique properties of the mentioned PSs allow 
bypassing such limitations of PDT as low specific uptake ratio, insufficiently broad 
absorption band, and low efficacy in hypoxia. One of these PSs (TLD-1433) was 
successful against non-muscle invasive urinary bladder cancer unresponsive to 
contemporary anticancer therapies.
Keywords: photodynamic therapy, photosensitizer, transition metal, Ru(II), Os(II), 
complex, transferrin, selectivity, tumor, cancer, urinary bladder
1. Introduction
Photodynamic therapy (PDT) is an actively developing anticancer modality that 
offers advantages compared to conventional treatments (ionizing radiation and 
chemotherapy). PDT utilizes two components, light and a photosensitizing com-
pound (PS) activated by light upon photon absorption and producing in its acti-
vated state highly cytotoxic reactive oxygen species (ROS) [1]. The attractiveness of 
PDT is in the use of safe nonthermal doses of light and nontoxic concentrations of 
the PS and evoking cytotoxic and immunologic effects upon activation of the PS by 
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light. PDT is supposed to selectively destroy unwanted and/or malignant cells while 
largely sparing the surrounding healthy tissue. Another desirable property is the 
ability to induce antigen-specific therapeutic and/or protective immune responses.
Preferential PS uptake by the tumors would make them exclusive targets for 
cytotoxicity while sparing normal tissues. Light delivery (both source location and 
emitted energy) can also be controlled more carefully (within the confines of the 
effective light attenuation in the tissue), which could make PDT a very efficient 
and safe modality. PDT effects reply upon a variety of photoreactions. The most 
commonly considered are the two types dependent on oxygen and associated with 
ROS production: electron transfer from the excited PS generating hydroxyl radical 
OH among other species (Type I) and energy transfer to a ground-state molecular 
oxygen 3O2 generating singlet oxygen 1O2 and superoxide radical anions (Type II) 
[2]. It is proposed that two more types are possible and are oxygen-independent: 
Type III as the interaction of the activated PS with native free radicals and Type IV 
as light-induced structural changes in PS allowing it to bind to subcellular targets [3].
PDT has been approved almost 20 years ago as an anticancer treatment. 
Nevertheless, despite the potential advantages, it is still underutilized clinically. 
Only a small number of porphyrin- and chlorine-like photosensitizers, as well as 
one bacteriochlorophyll-based PS, are approved. The number of indications for each 
photosensitizer is also very limited and includes primarily superficial cancerous/pre-
cancerous lesions and other conditions such as actinic keratosis, basal cell carcinoma, 
high-grade dysplasia in Barrett’s esophagus, and age-related macular degeneration. 
As a palliative measure, PDT is approved for obstructive esophageal or lung cancer 
and centrally located lung cancer [4, 5]. There are several reasons for this.
One of them is a small depth of penetration of visible light into the tissues 
restricting PDT to superficial lesions with a thickness not exceeding few mil-
limeters. For deeper organs/tissues, an invasive direct delivery of light is required. 
Light absorbance of longer wavelengths by the PSs is therefore very advantageous. 
Light in the range of 650–1350 nm (known as “near-infrared window”) [6] has the 
greatest penetrating ability into biological tissues. This includes parts of red (625–
740 nm) and near-infrared (>750 nm) range that can be used for the PS activation.
Another problem is an unsatisfactory selectivity for malignant tissues resulting 
in PDT-associated damage of normal tissues. For example, Photofrin® is known for 
this [4]. Prolonged retention of many porphyrin-based PSs in healthy tissues leads 
to a problem of sensitivity to sunlight and potentially serious damage to the patients’ 
skin and eye [7, 8]. This could be mitigated by delivery systems selectively targeting 
malignant cells. These systems employ two modes of action [9]. Passive targeting 
relies upon the morphological and physiological peculiarities of tumor tissue in 
combination with physicochemical properties of the PS carrier. Active targeting, in 
contrast, is based on a molecular recognition of the PS carrier by cancer cells such 
as binding of specific ligands or antibodies to overexpressed cancer cell receptors. 
Passive PS delivery systems include nanoparticles, fullerenes, and liposomes and 
have the advantage of protecting the PS from degradation upon injection. Active 
systems, on the other hand, have the advantage of improved uptake of the PS. The 
carriers belonging by themselves to passive targeting systems can be nevertheless 
supplemented with molecular recognition capacity belonging to the features of active 
systems, such as decoration with Tf to target Tf receptors overexpressed in malignant 
cells [10–12]. Nevertheless, smaller active targeting systems (such as PS-Tf conjugates 
discussed further in this chapter) could have an advantage of greater mobility upon 
intracellular uptake and potentially the advantage of the blood-brain barrier crossing.
Lastly, PDT-induced ROS production strongly relies upon oxygen availability, 
which is well known for the porphyrin-based PSs [13, 14]. Deep bulky tumors have 
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extensive hypoxic regions, which are also associated with the tumor aggressiveness 
[15, 16]. Although hypoxic regions still can be treated (at a slower rate) by applica-
tion of fractionated exposure or inducing reperfusion [17, 18], hypoxia severely 
decreases PDT efficacy [19]. Together with the limited light penetration, this is 
another reason why PDT in its current state is usually limited to relatively superfi-
cial lesions. This problem could be bypassed by PSs employing photoreactions that 
have little or no dependency on oxygen.
Considering the said above, an advanced PS should have the ability for targeted 
delivery; penetration through the blood-brain barrier (BBB) and blood-tumor cell 
barrier (BTCB); activation by a wide range of wavelengths, including NIR light; 
and employing of different types of photoreactions enabling induction of immune 
responses to tumor antigens. Solubility in water and/or saline is a great asset for a 
successful PS as it makes its delivery both easier and safer, without the use of excipi-
ents with potential toxicity/side effects on their own.
Metal-based coordination complexes are among the obvious candidates to 
satisfy these requirements. Specifically, transition metal complexes possess a 
wide range of metal oxidation states and the complex geometries [5, 20]. These 
complexes (e.g., Ru(II) polypyridyl complexes) are of increasing interest as PSs in 
photodynamic therapy (PDT) and, more recently, for photochemotherapy (PCT) 
[21]. Importantly, they can have their properties fine-tuned by choosing the 
central metal and organic ligands (such as bipyridine and 2,2′-biquinoline). These 
PSs can employ a great variety of excited states associated with the central metal, 
ligands, or metal-ligand interactions. This is manifested in photoreactions that are 
ROS-dependent (Type I/II) or ROS-independent (electron transfer to substrates 
other than molecular oxygen), excitation at different wavelengths, solubility, 
systemic toxicity, and finally PDT efficacy. Historically, Pt(IV)-, Ru(II)-, and 
Rh(III)-based complexes were most actively studied as PSs followed by Ir(III) and 
Os(II) complexes; see the review by Monro et al. [5]. The examples of the most 
recent studies [22–26] include a summary on the use of ruthenium complexes as 
PSs in PDT [27].
This chapter reviews the results obtained by our group and collaborators. The 
properties and PDT efficacy of Theralase Technologies Inc. PSs [28] and Ru(II)- and 
Os(II)-based complexes are discussed in the perspective of their clinical application.
2. Physical and chemical properties of the transitional metal-based PSs
2.1 Molecular structure
The molecular structure of Ru(II)- and Os(II)-based PSs (later referred to as 
Ru- and Os-based) is shown in Tables 1–3. These are relatively small (approxi-
mately 1 kDa) complexes with the ligands involving bipyridine (bip), 2,2′-biqui-
noline (biq), imidazo[4,5-f ][1,10]phenanthroline, and a variable number of 
thiophene units. A variety of the ligands defines some of the PS properties. 
For example, the biq ligand is responsible for relatively good absorbance in 
near-infrared (NIR) light, while the number of thiophene units may be associ-
ated with the PS solubility in water [5]. Water solubility, as it was mentioned, 
represents a serious advantage for this group of PSs as many of the established 
PSs have poor water solubility [29, 30]. Ru-based PSs are characterized by 1O2 
quantum yield that is much higher (up to 99%) than for the established (FDA-
approved) porphyrin-based PSs: PPIX, an active metabolite of ALA (0.56) and 
Photofrin (0.89).
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TLD-1011
MW = 868.8
1O2 quantum yield
= 0.74
Fluorescent quantum yield
= 0.001
TLD-1411
MW = 950.9
1O2 quantum yield
≈ 0.99
Fluorescent quantum yield
< 0.01
TLD-1611
MW = 1033.1
1O2 quantum yield
n/d
Fluorescent quantum yield
n/d
TLD-1433
MW = 1007.1
1O2 quantum yield
≈ 0.99
Fluorescent quantum yield
< 0.01
TLD-1633
MW = 1089.2
1O2 quantum yield
n/d
Fluorescent quantum yield
n/d
Table 1. 
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TLD-OsH2B
MW = 954.0
1O2 quantum yield = 0.035
Fluorescent quantum yield
= 0.0011
TLD-OsH2IP
MW = 994.0
1O2 quantum yield = 0.044
Fluorescent quantum yield =0.0008
TLD-Os10H
MW = 1158.2
1O2 quantum yield = 0.035
Fluorescent quantum yield =0.0013
TLD-Os14H
MW = 1240.3
1O2 quantum yield = 0.03
Fluorescent quantum yield =0.0009
TLD-OsH2dppn
MW = 1106.1
1O2 quantum yield n/d
Fluorescent quantum yield
n/d
Table 2. 
Molecular structures of Os(II)-based complexes. Quantum yields are measured in solution rather than in cells.
Tumor Progression and Metastasis
6
2.2 Absorbance spectra
The absorbance spectra of the Ru- and Os-based PSs are shown in Figure 1. Among 
the Ru-based PSs, methylation of bidentate ligands (bip) decreases absorbance. An 
increase in the number of thiophene rings redshifts the main absorbance peak and 
eventually results in a considerable increase in absorbance at longer wavelengths (see 
TLD-1633).
Os-based PSs having biq ligands, in contrast to the Ru-based PSs, have similar 
spectra. They demonstrate rather uniformly located strong main peak at approxi-
mately 340 nm attributed to ligand-centered transitions and a characteristic 
secondary peak at ≈550 nm attributed to metal-to-ligand charge transfer (MLCT) 
centered on the non-biq ligands. Importantly, these PSs demonstrate consistent 
Figure 1. 
Absorbance spectra of the Ru(II)- and the Os(II)-based PSs (panels A and B, respectively) in water.
Bipyridine
Methylated bipyridine
Imidazo[4,5-f][1,10]phenanthroline
Thiophene
2,2′-biquinoline
benzo[i]dipyrido[3,2-a:2′,3′-c]phenazine
Table 3. 
Ligands involved in the PSs’ molecular structure.
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absorbance at longer wavelengths (red to NIR range). The NIR absorbance is 
attributed to MLCT that involves biq ligands. Altogether, the spectra similarity 
suggests similar accessible electronic transitions and ground and excited states. 
Broad absorption band of the Os-based PSs allows for a wider range of photon 
attenuation coefficients. Considerable absorbance in a clinically important PDT 
window of 700–900 nm suggests a capacity for one-photon absorption [31]. This 
asset is emphasized by a good solubility of these PSs in water. Poor solubility in 
water may hamper PDT potential of PSs even with a good absorbance in this range 
of the spectrum, as in the case of porphyrin- and phthalocyanine-based PSs [32]. 
The inclusion of thiophenes and the increase in their number in the ligands (from 
TLD-OsH2B to TLD-Os14H) not only decreases the main absorbance peak but 
also markedly redshifts its shape, with a minimal effect on the secondary peak and 
absorbance in the longer wavelengths (Figure 1B).
2.3 Photobleaching resistance
If the PS is resistant to photobleaching, this allows less PS being destroyed by the 
light exposure. In turn, this makes ROS production and subsequent cytotoxic action 
more efficient, because the process of conversion of photons to cytotoxicity becomes 
catalytic without stoichiometric consumption of the PS. This allows making the effi-
cacy of PDT treatment independent on the availability of the PS during the treatment.
The bleaching resistance is hence a very valuable property, especially if the 
delivered light energy must be increased to achieve the desired PDT efficacy. This 
could be a drawback though in the case of bleaching-based dosimetry during the 
treatment [33, 34].
Ru-based PSs show notable bleaching under exposure to green light (525 nm). 
TLD-1433 is slightly more bleaching resistant than TLD-1411 although they have 
almost identical absorbance at 525 nm. Nevertheless, more than 50% of each PS 
remains intact even after 200 Jcm−2 of radiant exposure corresponding to 6.6x1019-
absorbed photons per cm3. Moreover, while bleaching results in the deterioration of 
the 416–417 nm UV peak, TLD-1433 absorbance in clinically useful range rapidly 
increases (1.7-fold at 525 nm, 2.0-fold at 625 nm, 1.8-fold at 800 nm) and remains 
at this level up to the end of light exposure (200 Jcm−2).
Os-based PSs having biq ligands show variable bleaching resistance under green 
light (525 nm); TLD-OsH2B is the most resistant and TLD-OsH2dppn the most vul-
nerable. Compared to the Ru-based PS, the bleaching resistance of the Os-based PSs 
with biq ligands is greater in general, with at least 75% of their initial absorbance 
retained. The best performers, TLD-OsH2B and TLD-OsH2IP, showed no more 
than 10% loss of absorbance in the UV peak, with no absorbance loss in green-NIR 
range. This provides the photobleaching rates in aqueous solution (calculated based 
on the incident irradiance) equal to 8.7*10−28 M hυ−1 cm−2 for TLD-OsH2dppn, 
4.1*10−27 M hυ−1 cm−2 for TLD-OsH2IP, and 1.5*10−26 M hυ−1 cm−2 for TLD-OsH2B 
[31]. For comparison, the photobleaching rate for the approved PSs can be much 
higher (by several orders of magnitude): 5.6*10−24 M hυ−1 cm−2 for benzoporphyrin 
derivative mono acid A (BPD), 7.3*10−23 M hυ−1 cm−2 for PPIX, and 4.8*10−16 M 
hυ−1 cm−2 for curcumin [35–37].
2.4 ROS production
Production of ROS represents a final event of the PS activation by light 
leading to PDT cytotoxicity. Ru-based TLD-1433 is able to generate hydroxyl 
radical *OH under red light (625 nm, 119 mWcm−2), although singlet oxygen 
1O2 production is not detected. Importantly, ROS is generated despite very low 
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absorbance of TLD-1433 in red light. This, however, requires certain molecular 
and ionic environment because ROS is generated only in incomplete DMEM cell 
culture medium (not complemented with FBS and antibiotics) but not in DI 
water despite almost identically low absorbance.
Exposure to NIR light (808 nm, 720 mWcm−2) produces some amount of ROS 
(*OH), but it at least an order of magnitude less than under red light. This occurs 
despite a similar number of absorbed photons and absorbance at 808 nm only 18% 
less than at 625 nm and greater delivered energy. This may suggest that not only 
the total delivered energy and number of the absorbed photons but also the photon 
energy is important for the efficacy in ROS production.
3. Association of the PSs with transferrin
3.1 Delivery platforms
To address the challenge of selective uptake of the PSs by tumors, it would be 
attractive to utilize serum proteins and natural transmembrane transporters as 
delivery vehicles. Despite numerous approaches for targeted delivery of the PSs 
including receptors-assisted uptake (as mentioned in the chapter introduction), 
neither is related to the use of Tf as a vehicle for transition metal-based complexes. 
The notable exceptions are the works on the interaction between Tf and Cr(III) 
complexes [38, 39]. It is also known that Ru(II) complexes can associate with 
albumin and iron transporter transferrin (Tf) [40, 41]. In addition, overexpression 
of Tf receptors is a common feature of malignant cells that tend to have an increased 
Fe3+ uptake [42]. The effect of the association of Ru(II)-based PSs with Tf on their 
photophysical and photobiological properties needs however more elucidation.
3.2 Association signatures and effect of Tf on absorbance spectra
Upon subtraction of the spectra of the complex and Tf from the spectrum 
of their premix, a characteristic signature of association between the Ru-based 
complex and Tf can be detected, with two peaks in UV and visible range. The UV 
peak indicates conformational changes in aromatic rings (the complex itself or 
transferrin molecule), and the visible range peak is interpreted as an indicator of 
LMCT (ligand to metal charge transfer) that represents the interaction between the 
metal of the complex and transferrin [43].
Premixing of Ru-based complexes with apo-Tf (the Tf not saturated with Fe3+) 
at 4:1 molar ratio demonstrates the signature with UV and visible range peaks 
(Figure 2A). The absorbance increase in UV range could be due to conformation 
changes either in the Tf molecule or the complex (as both have UV maxima at 
similar wavelengths). The peak in visible range indicates a new spectral component 
distinct (redshifted) from the comparable absorbance peak for the PS alone. This 
indicates the complex-Tf association and is related to the interaction between the 
metal in the complex and the Tf molecule.
There is also an increase in absorbance between the signature peaks and, impor-
tantly, in the long wavelength tail of the spectrum in the visible range and further into 
the NIR, which is clinically relevant for PDT. Notably, the absorbance of TLD-1433 
alone is very low in red to NIR. The increase in absorbance upon the association 
with Tf is 16.2-fold (MEC = 3125 vs. 193 M−1 cm−1) in red (635 nm) and 5.7-fold 
(MEC = 1676 vs. 294 M−1 cm−1) in NIR (800 nm), compared to 5.0-fold (MEC = 8027 
vs. 1600 M−1 cm−1) increase in the green (535 nm). Notably, the ability of the PS to 
associate with Tf depends on the number of thiophene rings in the complex. One 
9Anticancer Photodynamic Therapy Using Ruthenium(II) and Os(II)-Based Complexes…
DOI: http://dx.doi.org/10.5772/intechopen.88519
thiophene ring is not enough for this as evident for TLD-1011. Hence, not only metal 
but also organic ligands play a role in the association of the complex with Tf.
The association signatures seem to be insensitive to the source of apo-Tf and 
are very similar for bovine and human Tf. The signatures resemble the signature of 
Fe3+−Tf binding but are not identical to it. Notably, TLD-1433 can also be associated 
with Fe3+ saturated holo-Tf although the magnitude of the association signature is 
lesser than for apo-Tf [43].
Os-based PSs with biq ligands are also able to associate with apo-Tf, but their 
signatures (Figure 2C) are distinct from those of Ru-based PSs. The visible range 
peak (observed for TLD-OsH2B and TLD-OsH2dppn but not for TLD-OsH2IP) is 
however more redshifted (in the range of 500–600 nm), and the signature magni-
tude is much lesser.
3.3 Stability of the TLD-1433 + Tf association at low pH
Physiologically, when Tf bound with Fe3+ is taken up into a cell, it releases iron in 
endosomes when pH is decreased to ≈5.5 [44]. TLD-1433-Tf conjugate, in contrast, 
remains stable during the gradual acidification emulating this process [43]. This 
is evident by the stability of absorbance at the two peaks of the signature across 
different pH values.
Notably, an association of TLD-1433 with holo-Tf also survives the acid environ-
ment. The magnitude of the signature peaks is 31–33% lower than for TLD-1433 
& apo-Tf at pH = 7.4, but by pH = 5 it increases so the UV peak magnitude catches 
up with that of TLD-1433 & apo-Tf, and the visible peak magnitude even becomes 
about 20% greater. Hence, TLD-1433 may remain associated with Tf in the acidic 
endosome environment. Acidification resistance does not hold however for the 
Figure 2. 
Spectral signatures of association of the Ru(II)-based (panel A) and Os(II)-based (panels B and C) PSs 
with apo-Tf. The incubation of Ru-based PSs was performed in 10 mM phosphate buffer +100 mM NaCl 
(pH = 7.4) and of Os(II)-based PSs in the phosphate buffer (panel B) or incomplete RPMI1640 cell culture 
media (panel C).
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increased absorbance in green to NIR range. The increase in red-NIR range due to 
the association of TLD-1433 with Tf deteriorates completely at low pH, and only in 
the green range, it shows some resistance: 16% remaining for TLD-1433 & apo-Tf 
and 66% for TLD-1433 & holo-Tf.
3.4 Effect of Tf on photobleaching
Association with Tf markedly decreases the extent and rate of photobleaching of 
TLD-1433 under green light (525 nm, 130 mWcm−2). At 0.93*1020 absorbed photons 
per cm3, more than 59% of TLD-1433 remains intact in 1:1 TLD-1433 & Tf premix. 
At the comparable absorbed light (0.23*1020 absorbed photons per cm3), 74% of 
TLD-1433 in the premix persists compared to 45% of TLD-1433 alone [43]. As 
mentioned above, a decreased bleaching allows for more efficient ROS production 
with less PS expended, so the advantage of TLD-1433 & Tf conjugate is evident.
3.5 Effect of Tf on ROS production
Association of TLD-1433 with Tf dramatically increases ROS production upon 
irradiation with red light (625 nm, 119 mWcm−2). In this case, 1O2 is generated, 
which does not happen with TLD-1433 alone. The production of *OH is increased 
twofold at 1.9*1022 absorbed photons per cm3 [43]. The association with Tf is 
therefore advantageous for ROS production considering that *OH is not only an 
extremely cytotoxic ROS but can also be produced from 1O2 [45]. The association 
with Tf is, however, unable to improve ROS production by TLD-1433 under NIR 
(808 nm, 720 mWcm−2) despite the increase in absorbance in this range.
4. In vitro PDT
Transition metal-based PSs hence are able to absorb light at clinically relevant 
wavelengths and produce cytotoxic ROS, and the association with Tf is beneficial 
in that. This warrants assessment of this capacity in biological systems. In vitro, 
the PDT effects are tested using clinically relevant human cancer cell lines (human 
glioblastoma U87 cells, human bladder cancer HT1376 cells) or nonhuman cells 
relevant for preclinical models (rat bladder cancer AY27 cells).
4.1 Ru-based PSs
The comparative efficacy of the Ru-based PSs on U87 cells is shown in Table 4. 
PDT efficacy of the Ru-based PSs can be very efficient in green light (LD50 in 
sub-nanomolar range) and moderately efficient in red light (LD50 in micromolar 
range in red light), but they are not active in NIR light. Notably, the efficacy of the 
PSs in red light is observed despite negligible absorbance (measured in water). In 
complete cell culture medium (and potentially intracellularly), absorbance in red 
is increased due to associaiton of the PSs with proteins but is still low compared to 
that at the shorter wavelengths.
Depending on the PS, the maximal PDT effect did not reach 100% cell kill. The 
data at 45 Jcm−2 PDT are not shown, but the increase in the light radiant exposure 
from 45 to 90 Jcm−2 significantly (P < 0.05) decreased LD50 for the PDT effect in 
green light. In red light, the PDT efficacy also could be increased with the increase in 
the radiant exposure from 45 to 90 and then to 180 Jcm−2. This can be explained by 
the insufficient number of incident photons per a given concentration of the PS at 
lower radiant exposure but not by a difference in quantum efficacy of the PDT that 
11
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depends only on the photon energy but not on the radiant exposure. The increase 
in the number of thiophenes in the PS complexes decreases LD50 for the green light 
and hence increases PDT efficacy. The dark toxicity is however also increasing. In 
HT1376 cells, LD50 in red light (90 Jcm−2) is 15.0 μM (CI95 = 9.1–24.9 μM, N = 30). 
U87 cells Dark Green Red NIR
530 nm 625 nm 808 nm
90 Jcm−2 90Jcm−2 400-600 Jcm−2
108 mWcm−2 125 mWcm−2 150 mWcm−2
TLD-1411 LD50 (μM): 101.5 
(CI95 = 87.8–117.4)
LD50 (μM):0.00595 
(CI95 = 0.0050–0.0074)
LD50 (μM): 0.909 
(CI95 = n/d-12.36)
Insufficient cell 
kill
Maximal kill (%): 49.41 
(CI95 = 46.9–52.0)
Maximal kill 
(%): 71.17 
(CI95 = 33.7–124.1)
N = 28 N = 9 N = 5
MEC (water) 2520 151 86
TLD-1433 LD50 (μM): 192.9 
(CI95 = 146.8–253.3)
LD50 (μM): 0.00702 
(CI95 = 0.00261–
0.01891)
LD50 (μM):3.57 
(CI95 = 2.99–4.40)
Inconsistent and 
low cell kill
Maximal kill (%): 65.9 
(CI95 = 59.1–72.8)
Maximal kill (%): 
76.2(CI95 = 66.7–
85.8)
N = 118 N = 32 N = 32
MEC (water) 3094 158 294
TLD-1611 LD50 (μM): 62.9 
(CI95 = 44.9–92.5)
LD50 (μM): 0.002 
(CI95 = 0.00117–0.0040)
Inconsistent and 
low cell kill
No cell kill
Maximal kill (%):74.8 
(CI95 = 65.7–83.9)
N = 31 N = 9
MEC 24,263 4635 1167
TLD-1633 LD50 (μM): 31.13 
(CI95 = 14.85 to 
63.68)
LD50 (μM): 0.000574 
(CI95 = 2.403e-006–
0.005691)
Inconsistent and 
low cell kill
No cell kill
Maximal kill (%): 100.8 
(52.2–171.0)
N = 14 N = 6
MEC (water) 7468 741 0
Photofrin® LD50 (μM): 2974 
(CI95 = 245.5–
36,027)
LD50 (μM): 0.20 
(CI95 = 0.16–0.25)
LD50 (μM): 0.23 
(CI95 = 0.17–0.31)
No cell kill
Maximal kill (%): 79.7 
(CI95 = 72.5–87.0)
Maximal kill 
(%): 91.8 
(CI95 = 83.2–100.4)
N = 45 N = 18 N = 26
MEC (water) 6947 3046 209
The cells were incubated with the PS for 4 h, and the PS was removed before PDT. The dose–response provides LD50 
(μM) and maximal cell kill (%) for a green and red light and a cell kill for a fixed PS concentration for NIR light. 
The data are presented as means and their 95% confidence intervals (SEM for NIR PDT).
Table 4. 
In vitro PDT efficacy of Ru(II)-based PSs on U87 cells, in comparison to the FDA-approved Photofrin®.
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This is a greater value than for U87 cells and suggests lesser PDT sensitivity. The total 
PDT cell kill is however high, 98.5% (CI95 = 85.6–111.4%). Dark toxicity is, in con-
trast, low, with LD50 exceeding 200 μM. Importantly, the efficacy of the Ru-based 
PSs exceeds the efficacy of FDA-approved Photofrin® in green light, although not 
in red light (Table 4). Judging by LD50, the Ru-based PSs have higher dark toxicity 
than Photofrin®, but this is of less importance because, in addition to their solubil-
ity in water, they are effective at much lesser, nontoxic concentrations.
Pure PDT effect elucidates the PS efficacy for PDT neglecting its dark toxicity, which 
is justifiable scientifically to reveal mechanisms of the PS action. Clinically, how-
ever, in the case of selective uptake of the PS into cancer cells vs. normal cells, 
cancer cell kill can be achieved both by PDT-mediated and cytotoxic mechanisms, and  
the total PDT-induced cell kill becomes relevant. Considering this, total cell kill 
close to 100% can be achieved in green light in sub-micromolar (20 nM for TLD-
1633, 30 nM for TLD-1433, and 200 nM for TLD-1411) or even sub-nanomolar 
range (0.5 nM for TLD-1611). For comparison, Photofrin® achieved 100% total cell 
kill in U87 cells only at concentrations above 300 nM.
Clinically, the balance between the efficacy and safety of the PS is character-
ized by the therapeutic ratio that indicates how far a dose for a desired therapeutic 
effect is from the dose that causes undesired toxicity. Dividing PDT effect LD50 
to dark toxicity LD50 provides small numbers that are not convenient to operate 
with. It is easier therefore to use inverted therapeutic ratio, ITR = Dark LD50/PDT 
effect LD50. In U87 cells, ITR = 17,061 for TLD-1411, 27,486 for TLD-1433, 31,460 
for TLD-1611, and 54,252 for TLD-1633 under green light PDT. This exceeds the 
ITR = 14,870 for Photofrin® and shows thus a clear clinical advantage of Ru-based 
PSs over an established porphyrin-based PS.
4.2 Os-based PSs
The comparative efficacy of the Os-based PSs on U87 cells is shown in Table 5.
Additionally, in HT1376 cells, TLD-OsH2IP has a dark LD50 > 200 μM, 
N = 43, red light PDT LD50 = 15.0 μM (CI95 = 9.1–24.9, N = 30), and a NIR 
light PDT LD50 = 39.0 μM (CI95 = 30.6–49.6, N = 5). TLD-OsH2dppn has dark 
LD50 = 203.2 μM (CI95 = 190.2–217.1, N = 61), red light PDT LD50 = 4.1 μM 
(CI95 = 2.9–5.7, N = 26) and NIR light PDT LD50 = 27.4 μM (CI95 = 7.2–100.4, N = 9).
The presence of imidazo[4,5-f][1,10]phenanthroline and adding dppn to the com-
plex increase PDT efficacy of the Os-based PSs, although it does not exceed the efficacy 
of Ru-based PSs. Similarly to the PDT LD50, ITR of the Os-based PSs in red light is also 
not better than that of Photofrin®; in U87 cells, ITR = 4.9 for TLD-OsH2B, 24.8 for 
OsH2IP, and 14.7 for TLD-OsH2dppn. In HT1376 cells, ITR > 13.3 for TLD-OsH2IP and 
equals to 49.6 for TLD-OsH2dppn. The advantage of the Os-based PSs, however, is their 
PDT activity in NIR light, which both Ru-based PSs and Photofrin® are lacking. ITR 
for NIR PDT is greater than 5.1 for TLD-OsH2IP and equal to 7.4 for TLD-OsH2dppn.
Another set of experiments focused at three Os-based PSs with bis ligands [31] 
supplements the data on red light PDT (625 nm, 90Jcm−2, 450 mWcm−2). In U87 
cells, TLD-OsH2IP is the most efficient PS (LD50 = 57 ± 4 μM) exceeding both TLD-
OsH2dppn (LD50 = 87 ± 12 μM) and TLD-OsH2B (125 ± 12 μM). In HT1376 cells, 
TLD-OsH2dppn is the most efficient (LD50 = 83 ± 4 μM); the remaining two PSs 
have similar LD50 (121 ± 10 μM for TLD-OsH2B and 141 ± 14 μM for TLD-OsH2IP). 
The inferiority of TLD-OsH2B in red light over the two other PSs is best reproduced 
across the presented datasets although comparative efficacy of TLD-OsH2IP and 
TLD-OsH2dppn is less consistent.
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Importantly, the dataset presented in [31] provides LD50 for NIR PDT (808 nm, 
600 Jcm−2, 900 mWcm−2), in contrast to the cell kill at a single concentration 
presented in Table 5. TLD-OsH2IP proves to be most effective among the three in 
U87 cells (LD50 = 45 ± 5 μM), whereas TLD-OsH2B was the most effective PS for 
HT1376 cells (LD50 = 121 ± 8 μM). For this wavelength, therefore, the efficacy of 
TLD-OsH2dppn was the lowest, in contrast to the red light PDT.
Concentration-wise, the PDT efficiency is almost always similar in red and NIR 
light. The exception is greater efficacy of TLD-OsH2dppn in red vs. NIR in HT1376 
cells (P < 0.001). In U87 cells, ITR is 3.3–9.6 for red PDT and 4.2–12.0 for NIR 
U87 cells Dark Green Red NIR
530 nm 625 nm 808 nm
90 Jcm−2 90 Jcm−2 400-600 Jcm−2
108 mWcm−2 125 mWcm−2 150 mWcm−2
TLD-OsH2B LD50 (μM):395.7 
(CI95 = 323.4–
484.1)
LD50 (μM):36.0(CI95 
= 19.4–365.4)
LD50 (μM):81.5(CI95 
= 16.9–393.3)
Kill (%):32.1 
(SEM = 14.3)
Maximal kill (%): 70.7 
(CI95 = 19.9–121.6)
Maximal kill 
(%): 114.3 
(CI95 = 7.6–220.9)
N = 43 N = 7 N = 12 N = 4
MEC (water) 12,328 3632 2269
TLD-OsH2IP LD50 (μM):145.8 
(CI95 = 67.6–314.6)
LD50 (μM): 3.1 
(CI95 = 2.1–13.2)
LD50 (μM): 12.2 
(CI95 = 9.2–15.8)
Kill (%): 63.8 
(SEM = 13.5)
Maximal kill (%): 
(CI95 = 30.67–107.9)
Maximal kill 
(%): 54.0 
(CI95 = 51.5–56.6)
N = 20 N = 10 N = 4 N = 4
MEC (water) 10,761 3119 1957
TLD-
OsH2dppn
LD50 (μM): 179.1 
(CI95 = 112.6–
284.8)
LD50 (μM): 0.16 
(CI95 = 0.08–0.34)
LD50 (μM): 12.2 
(CI95 = 0.7–577.6)
Inconsistent and 
low cell kill
Maximal kill 
(%): 84.2 
(CI95 = 70.5–97.8)
Maximal kill (%): 79.1 
(CI95 = -2.0–160.3)
N = 20 N = 10 N = 4
MEC (water) 10,486 4828 2273
TLD-Os14H LD50 (μM): 141.2 
(CI95 = 107.8–
185.0)
LD50 (μM): 2.1 
(CI95 = 1.6–3.4)
LD50 (μM): 2.4 
(CI95 = 1.8–3.3)
Kill (%): 24.2 
(SEM = 4.7)
Maximal kill (%): 59.4 
(CI95 = 46.6–72.3)
Maximal kill (%):
78.2 
(CI95 = 69.0–87.5)
N = 54 N = 33 N = 53 N = 10
MEC (water) 11,716 2914 1376
The cells were incubated with the PS for 4 h, and the PS was removed before PDT. The dose–response provides LD50 
(μM) and maximal cell kill (%) for a green and red light and a cell kill for a fixed PS concentration for NIR light. 
The data are presented as means and their 95% confidence intervals (SEM for NIR PDT).
Table 5. 
In vitro PDT efficacy of Os(II)-based PSs on U87 cells (90 Jcm−2).
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PDT. In HT1376 cells, it is, respectively, 4.6–6.1 and 2.6–6.1. As in the dataset shown 
in Table 5, this is far behind the ITR value for Photofrin®, but considerable PDT 
activity in NIR is a decisive asset. This advantage is reinforced by the similar LD50 
for red and NIR PDT, which means that (at certain light exposure conditions) NIR 
PDT can be at least not worse than red PDT.
One should remember however that NIR PDT needs much more energy to 
be delivered, NIR range photons carry less energy, and absorbance is lesser 
than for the red range. Red light PDT is still more efficient per absorbed 
photon than NIR PDT because similar LD50 in μM is achieved at a much lesser 
number of absorbed photons (P < 0.001). Hence, the NIR PDT advantage of 
the Os-based PSs must be realized by increasing the delivered energy of light. 
This does not pose a problem because no thermal effects are observed for 
808 nm at 600 Jcm−2.
4.3 Effect of Tf on in vitro PDT efficacy
Additional apo-Tf increases red light PDT efficacy of the Ru-based TLD-1433 in 
AY27 cells, together with a decrease in dark toxicity [43]. The PDT improvement 
effect is however significant (PDT effect LD50 = 11.6–11.9 μM vs. 17.0 μM with no 
additional Tf, P < 0.05) only after a relatively short (30 minutes) TLD-1433 incuba-
tion before PDT. If the incubation time is increased to 90 minutes, the beneficial 
effect of the additional Tf is not anymore evident, masked by the increased TLD-
1433 PDT efficacy.
4.4 PDT efficacy in hypoxia
Hypoxia in tumors is one of the major challenges for anticancer therapy because 
both conventional radiotherapy and PDT rely upon oxygen, a mediator of damage 
to cancer cells. It is known at the same time that the tumors with hypoxic cores are 
clinically more aggressive [15].
This means that any modality effective under hypoxic conditions is extremely 
valuable. Among the four Ru-based and six Os-based PSs, Ru-based TLD-1633 and 
Os-based TLD-OsH2B proved to be active in hypoxic conditions (at 0.1–0.5% O2) 
after red light PDT (625 nm, 90 Jcm−2, 125 mWcm−2). Incubation with ALA (having 
its metabolite PPIX as photosensitizer) is used as a negative control (an oxygen-
dependent PS). For TLD-1633, hypoxia resistance is observed at a concentration as 
low as 4 μM, with significantly non-zero PDT effect = 67.3% cell kill in normoxia 
(P = 0.022) and 46.2% in hypoxia (P = 0.036), at moderate (25% cell kill) dark 
toxicity. For TLD-OsH2B, PDT effect is evident only at 320 μM. PDT effect reaches 
significantly non-zero effect: 59.8% in hypoxia (P = 0.006) vs. 42.2% in normoxia 
(P = 0.0006), and at considerable (53% kill) dark toxicity. For both PSs, hypoxia 
resistance occurs at concentrations above the PDT LD50.
It is noteworthy that TLD-1633 is active at low oxygen concentration cor-
responding to pO2 = 0.76 mmHg. It is very encouraging because it is known that 
anticancer efficacy of conventional treatment progressively decreases at pO2 below 
a critical threshold of 15–35 mmHg [46, 47].
High dark toxicity of the OsH2B hypoxia-effective concentration is a clear limi-
tation, but this demonstrates anyways a possibility of hypoxia-effective Os-based 
PSs that, as it was shown, have also PDT activity in NIR. NIR light has greater pen-
etration depth into tissues than visible light, and this, together with the PS activity 
under hypoxia, will pose a double benefit for PDT of bulk tumors.
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5. In vivo PDT
5.1 Selective uptake by tumors
Intracellular accumulation of TLD-1433 was detected earlier, and association 
with Tf facilitated this process [43]. Hence, one needs to explore whether this 
translates to the selectivity of TLD-1433 uptake into tumors in vivo.
TLD-1433 is able to accumulate selectively in tumor tissue vs. normal ones even 
without premixing with Tf. In AY27 rat urinary bladder tumors, characteristic 
staining can be seen co-localized with tumors (Figure 3) 1 h after instillation of 
50 μg/mL TLD-1433.
TLD-1433 accumulation in the tumors is at least one order of magnitude greater 
than in the adjacent apparently normal tissue: 77 ± 18 mg/kg, N = 6 vs. 0.4 ± 0.09, 
N = 6, P = 0.007.
The concentration in a tumor, therefore, reaches estimated 76 μM, which is far 
exceeding in vitro PDT effect LD50 for U87 cells in green light (Table 4). Moreover, 
the foci of coloration are visible outside of a major tumor. This suggests a possibil-
ity of detection of very small malignant lesions not readily visible macroscopically 
without staining by the PS.
Association of TLD-1433 with apo-Tf is able to increase selectiveness of the PS 
accumulation in subcutaneous CT26.WT (murine colon adenocarcinoma) tumors in 
BalbC mice (Figure 4). Four hours after systemic injection of 10 mg/kg TLD-1433 
premixed with apo-Tf (molar ratio = 1:1), significantly more TLD-1433 is found in a 
tumor vs. adjacent muscle tissue (P = 0.038); the selectivity ratio is about 1.8. With 
TLD-1433 injected, the uptake into a tumor is not significantly different from the 
adjacent muscle tissue.
Averaging of the individual tumor/muscle uptake ratios for each animal confirms 
the results shown above. The ratio is significantly above 1 upon injection of the TLD-
1433-Tf premix (1.81 ± 0.14, N = 5, P = 0.005) indicating the uptake selectivity. With 
TLD-1433 alone injected, the uptake into the tumors is not selective (0.74 ± 0.18, 
N = 4, P = 0.247). This firmly suggests that the association of TLD-1433 with apo-Tf 
increases selectivity of TLD-1433 uptake by a tumor. Apo-Tf per se cannot be taken 
up because it has to bind Fe3+ to be recognized by the cell surface TfR. Since selec-
tive improvement of the uptake of TLD-1433 & apo-Tf premix by the tumors is 
Figure 3. 
Accumulation of TLD-1433 in AY27 orthotopic urinary bladder tumors in fisher rats. The bladder was 
examined 1 h after instillation of 50 μg/mL TLD-1433. The arrows denote the areas of coloration by TLD-1433 
implying its accumulation in the lesions.
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demonstrated, one can anticipate two possible scenarios: (1) TLD-1433 & apo-Tf 
still manages to bind Fe3+, and (2) TLD-1433 & apo-Tf conjugate can be recognized 
by TfR and taken up by the cell without the need to bind Fe3+.
5.2 In vivo PDT efficacy
5.2.1 Light penetration
Assessing PDT efficacy in vivo is a necessary step on the way to potential clinical 
applications. It has however its own challenges to be addressed. Light exposure 
regime is one of them.
The penetration depth of light at different PDT conditions is crucial for the 
PDT success. For example, a small penetration depth of green light is because 
of a strong attenuation by intrinsic chromophores, such as hemoglobins and 
cytochromes. The calculations estimate the energy attenuation up to 1/8 cm−1 in 
TLD-OsH2B MEC (in water) No PS 4.5 mg/kg 9 mg/kg
Green 12,328 0.10–15 0.10 0.01↓
Red 3632 0.60 0.30↓ 0.08↓
NIR 2269 0.55 0.22↓ 0.15↓
TLD-OsH2IP MEC (in water) No PS 2.25 mg/kg 3 mg/kg 9 mg/kg
Green 10,761 0.10–15 0.07↓ 0.005↓ 0.06↓
Red 3119 0.60 0.70 0.29↓ 0.05↓
NIR 1957 0.55 0.79 0.37↓ 0.08↓
TLD-Os14H MEC (in water) No PS 0.9 mg/kg 1.8 mg/kg 9 mg/kg
Green 11,716 0.10–15 0.04↓ 0.06↓ 0.06↓
Red 2914 0.60 0.22↓ 0.07↓ 0.05↓
NIR 1376 0.55 0.11↓ 0.08↓ 0.08↓
Table 6. 
Light attenuation in a phantom tumor (proportion of energy penetrating to the bottom of 1-cm-thick phantom 
vs. surface) in green (525 nm), red (635 nm), and NIR (808 nm) light.
Figure 4. 
Accumulation of TLD-1433 without or with apo-Tf at different molar ratios in CT26.WT tumors in BalbC 
mice 4 h after systemic (IV) injection (10 mg/kg). N = 5 for TLD-1433 & apo-Tf group; N = 4 for TLD-1433 
group.
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skin and 1/20 cm−1 in a tumor that has a higher density of vasculature and hence 
more absorbing chromophores [48]. High absorbance of light by the PS is a very 
desirable property contributing to its efficacy. This could be a double-edged 
sword however because high absorbance of the PS close to the tumor surface can 
shield the deeper tissue from the light exposure and hence result in undertreat-
ment of a tumor. The measurements using a tissue-emulating phantom (a piece of 
meat having a size of an experimental tumor with an overlaying piece of shaved 
mouse skin) show indeed that the Os-based PSs (TLD-OsH2B, TLD-Os2IP, and 
TLD-Os14H) affect the penetration of light into a tumor at different wavelengths. 
Without PSs, 85–90% of energy is lost across the tumor thickness (about 1 cm) 
for green (525 nm, 40 mWcm−2), 40% for red (635 nm, 150 mWcm−2) and 45% 
for NIR (808 nm, 300 mWcm−2) photons. The PSs injected into a tumor further 
diminishes the light penetration (Table 6).
It is noteworthy that the increase in light attenuation across the wavelengths 
is PS-specific. At the minimal used dose for each PS, TLD-OsH2B does not 
attenuate green light penetration, TLD-OsH2IP does not attenuate in red and 
NIR, while TLD-Os14H does this at all three wavelengths. Also, the increase 
in the PS concentration results in a progressive and disproportional increase 
in light attenuation. Notably, the absorbance of the PS measured in water (see 
Figure 1) is not translated directly into the PS-dependent light attenuation in the 
tumor phantom.
The limitations of light penetration can be also illustrated by the distribution 
of PDT-induced damage in tumors. The damage inflicted by red light (660 nm, 
90 J/cm−2, 125 mWcm−2) PDT to CT26.WT subcutaneous tumors in BalbC mice 
after systemic administration of 10 mg/kg of the 1:1 TLD-1433 & apo-Tf premix 
clearly diminishes as it goes deeper into a tumor (Figure 5C,D). The damage 
area is not necessarily decreased, but the magnitude of the damage has a definite 
gradient with coagulative necrosis near the surface and the “general damage” that 
cannot be defined as coagulative necrosis. The damage is incomplete even when 
TLD-1433 is associated with apo-Tf (which is expected to facilitate PDT effect 
as evident from in vitro experiments). Notably, the skin on the way of the light 
beam is not damaged, which can suggest selectivity of the PS uptake into a tumor. 
Considering that red light is still delivering 60% of the incident energy at 10 mm 
depth (Table 6), much more shallow damage (up to about 3 mm) suggests a steep 
gradient of PDT efficacy as the delivered energy falls below a certain threshold.
The observed damage should be clearly attributed to PDT but not dark toxicity 
of the PS in a tumor because, without light, there is no visible damage (Figure 5B).
Figure 6 shows representative examples of coagulative necrosis as a result of 
damage and a pattern of gradual transition of the damaged zone from an intact 
tumor to the necrotic area.
5.2.2 Thermal effect
Thermal effect is another consideration because it can potentially occur in a 
tumor upon light irradiation. For green light, this is possible due to absorption by 
intrinsic hemoglobin. Hyperthermia is known and used as an anti-tumor modality 
[49], but in PDT studies, the thermal effect may mask PDT-specific mechanisms of 
tumor damage.
In the subcutaneous tumor model (CT26.WT tumor in BalbC mice), 
continuous-wave irradiation with red (635 nm, 150 mWcm−2) or green (525 nm, 
40 mWcm−2) light does not show any signs of overheating at the tumor surface. 
The temperature does not exceed 31–35°C at the end of irradiation even with 
TLD-Os14H injected intratumorally.
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Figure 6. 
Coagulative necrosis and “general damage” in a PDT-treated tumor. The Panel a shows an example of 
coagulative necrosis area; the Panel b shows a gradient transition from non-damaged tumor area to the necrotic 
one through the area of “general damage”.
Figure 5. 
Tumor damage (H&E staining) after red light (660 nm, 90Jcm−2, 125 mWcm−2) PDT to CT26.WT 
subcutaneous tumors in BalbC mice after systemic administration of 10 mg/kg TLD-1433 as 1:1 TLD-1433 
& apo-Tf premix. The PDT was performed 4 h after the administration, and the tumors harvested 2 days 
post-PDT. The Panel a shows untreated tumor, the Panel b shows PS-injected tumor with no irradiation, and 
the Panels c-d show PDT-treated tumors.
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Within a tumor, a combination of deeper-penetrating light and less absorbance 
by the PS also does not result in considerable thermal effect. Under NIR light alone 
(808 nm, 600 Jcm−2, 300 mWcm−2), the temperature increases only by 4.8°C (from 
26.9 to 31.7°C) during 30 minutes of irradiation. In the presence of Ru-based TLD-
1433 (50 mg/kg intratumorally in 100 μL per 20 g BW), the temperature rapidly 
increases from 28.4°C to 33.6°C (by 5.2°C) at 50 Jcm−2 delivered to a tumor and only 
by 8.1°C at the end (600 Jcm−2). The temperature reaches no more than 36.5°C show-
ing no PDT-dependent thermal effect. TLD-1433 is responsible only for 3.3°C (41%) 
of the total PDT-induced increase. Notably, in euthanized animals, the total increase 
in temperature is similar to that in live animals (although with more linear increase 
dynamics). This may mean that the active removal of heat by circulating blood is not 
critical in maintaining the temperature within the safe range during PDT.
5.2.3 PDT effect
In CT26.CL25 subcutaneous tumor model in BalbC mice, intratumoral injec-
tion of TLD-1411 or TLD-1433 at 1/20 MTD (1.8 and 5.2 mg/kg, respectively) 
green (525 nm, 192 Jcm−2, 200 mWcm−2) light PDT resulted in a fast reduction 
or complete regression of the tumors and a temporary (8–9 days) delay in their 
growth [50]. This effect was statistically significant (P < 0.05) only for TLD-1433 
translating to an increased survival (about 15% of the animals surviving beyond the 
90 days follow-up period).
The dose of both PSs has to be increased to 1/2 MTD (18 and 52 mg/kg, respec-
tively) to obtain significant (P < 0.01–0.05) PDT effect of greater magnitude, with 
only continuous-wave PDT effective. About 50% of the animals survived beyond 
60 days for TLD-1411 and about 75% beyond 90 days for TLD-1433. Figure 7 shows 
an example of the PDT-induced tumor damage and subsequent regression.
Figure 7. 
An example of successful tumor destruction by 53 mg/kg TD1433-mediated PDT under continuous-wave green 
light (525 nm, 192 Jcm−2, 200 mWcm−2).
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These results are obtained with a green light that has only a superficial light 
penetration. TLD-1433-mediated (50 mg/kg =47% MTD) PDT using deeper-pen-
etrating NIR light (808 nm, 600 Jcm−2, 400 mWcm−2) does not reach however the 
efficacy of green light PDT despite 6.7 times greater radiant exposure [43]. Only a 
trend to improvement in survival (P = 0.164–0.179 vs. dark toxicity and light only) 
could be observed. This is not surprising by itself considering that TLD-1433 has 
extremely low absorbance in NIR. Nevertheless, the P values allow hypothesizing 
that a significant effect could be achieved with more powerful experimental design 
or greater delivered light energy.
More encouraging is a beneficial effect of combining TLD-1433 with Tf. A 
highly significant PDT effect in the animals survival can be observed when 4:1 
TLD-1433 & apo-Tf premix (50 mg/kg TLD-1433) is injected instead of TLD-
1433 only (P = 0.0182–0.0032 vs. dark toxicity and light only). No dark toxicity 
for tumors (effect of the premix with no light on tumor growth) is detected. 
Although the difference vs. TLD-1433-induced PDT (P = 0.0633) still does not 
reach statistical significance threshold, the P value, again, is small enough to talk 
about a trend toward the improvement. The result reinforces the valuable finding 
of the benefit of TLD-1433-Tf premix in PDT efficacy improvement under NIR 
light. This is especially noteworthy because the absorbance of TLD-1433-Tf in 
NIR range is still very low compared to the absorbance in green light despite the 
facilitating effect of Tf.
Anyways, 600 Jcm−2 NIR PDT is able to maintain about 70% of the animals 
surviving beyond 90 days follow-up (vs. only about 30% after PDT mediated by 
TLD-1433 that was not mixed with Tf), which is not less than survival after 192 
Jcm−2 green light PDT. This is especially encouraging considering that NIR PDT 
is not effective in vitro, either with or without Tf. The failure to detect in vitro 
PDT effect in NIR is possibly because the short-term viability assay (reflecting 
metabolic suppression rather than actual cell death) could be not sufficient to 
detect the effect of NIR that has less energy per photon. The effect in vivo, in 
contrast, is assessed by the long-term follow-up of tumor growth. The activity 
of the Ru-based complexes under NIR is known from literature [51] but involves 
multiphoton excitation. In contrast, the results presented above demonstrate the 
ability of the PSs to be activated by NIR in a continuous-wave regime via single-
photon excitation. Moreover, TLD-14333-Tf premix has an additional benefit of 
decreased systemic toxicity, with MTD more than twofold greater than that for 
injection of TLD-1433 only [50].
This double benefit of using apo-Tf as a delivery vehicle for TLD-1433 resembles 
the already mentioned effect in vitro for red light PDT using AY27 cells where 
TLD-1433-Tf decreased dark toxicity and increased PDT efficacy. Note however 
that in vitro experiments using cancer cell line determined dark toxicity in cancer 
cells and hence can be rather an estimate for dark toxicity of the PS in tumors. In 
contrast, in vivo model considered the benefit for systemic toxicity.
NIR PDT efficacy in vivo can be also demonstrated by direct quantitation of 
the tumor damage. Even suboptimal PDT (200 instead of 600 Jcm−2) shows a 
trend (P = 0.104, df = 8, one-tailed) to an increase in the relative area of damage 
in a tumor as compared to the tumors not subjected to PDT (dark and tumor alone 
data pooled). The damage area is increased to 33.4 ± 10.2% (N = 4) vs. 17.1 ± 2.5% 
(N = 6). The effect is only moderate and does not reach statistical significance, but 
this could be because of suboptimal (200 Jcm−2) radiant exposure.
Among the Os-based PSs (TLD-OsH2B, TLD-OsH2IP, TLD-OsH2dppn), the 
MTD values vary. TLD-OsH2B is the most toxic (MTD = 1.25 mg/kg) and TLD-
OsH2dppn the least toxic (MTD = 47 mg/kg), which is more than one magnitude of 
difference [31]. For comparison, in vitro dark LD50 for three PSs were much closer 
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to one another (416–617 μM for U87 cells and 476–744 μM for HT1376 cells). As it 
was mentioned already, however, in vitro dark toxicity for cancer cells and in vivo 
MTD as systemic toxicity is not directly comparable.
TLD-OsH2IP-mediated (3 mg/kg = 1/2 MTD) continuous-wave red light PDT 
(635 nm, 192 or 266 Jcm−2) significantly slows down the tumor growth and increases 
survival vs. light only group (P < 0.01). The effect is however temporary (like TLD-
1433, as discussed above). Increasing the radiant exposure to 266 Jcm−2 allows for a 
better result, with the cases of tumor regression and survival significantly increased 
vs. both dark and light only groups (P < 0.01) and about 80% of the animals surviv-
ing beyond the 50 days follow-up. Considering high photostability of TLD-OsH2IP, 
further increase in power and energy density for red light PDT is possible. This 
could potentially allow achieving complete tumor-suppressing success, at least in the 
framework of this in vivo model.
We have discussed previously that NIR effect is potentially possible even at 
suboptimal settings with Ru-based TLD-1433-Tf formulation. This formulation has 
an absorbance in NIR higher than TLD-1433 but still lower than Os-based TLD-
OsH2dppn (MEC = 777–1459 vs. 2273 M−1 cm−1, respectively). Hence, we could 
expect NIR PDT effect for TLD-OsH2dppn because this PS absorbs much better in 
NIR than TLD-1433. The PDT effect is indeed observed at 3 mg/kg of the PS and 
800 nm and 600 Jcm−2, with about 60% of the animals surviving beyond 50-day 
follow-up vs. dark and light only groups (P < 0.01 and 0.0001, respectively). This 
result further demonstrates the potential of NIR PDT application using transi-
tion metal-based PSs. The NIR PDT still requires delivery of at least 3 times more 
Figure 8. 
Damage to muscle noninvasive AY27 tumor induced orthotopically in fisher rats’ urinary bladder 2 days after 
TLD-1433-mediated green light (535 nm, 90 Jcm−2) PDT. TLD-1433 at 6 mg/mL was instilled into bladders, 
and PDT performed after 1 h of incubation and TLD-1433 washing out of the bladder cavity. The macroscopic 
image and H&E images are shown.
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photons than for red light PDT to match it in efficacy (considering the difference in 
absorbance and quantum energy), but this does not pose a serious problem because 
of thermal safety of the light exposure as it was discussed above.
Another anticancer application of PDT using transition metal-based PSs is 
urothelial non-muscle invasive bladder cancer [52]. As it was mentioned above, 
Ru-based TLD-1433 accumulated selectively in the orthotopic urinary bladder 
tumors (instillation with 0.05 mg/mL). At higher concentration of TLD-1433 
(6 mg/mL) that is more relevant for the future clinical applications, green light 
(535 nm, 90 Jcm−2) PDT causes full depth (2–3 mm) necrosis in a tumor that 
showed a deep red coloration (Figure 8). Importantly, PDT spared the muscle and 
urothelial tissue adjacent to the tumors, with only a transient local inflammation of 
the adjacent urothelium. This is a decisive advantage because the collateral muscle 
damage impairing the bladder function was a reason for the failure of the prior 
clinical trials on bladder cancer PDT.
6. Clinical PDT efficacy
The results of the preclinical research allowed planning and initiation of a clini-
cal trial for non-muscle invasive bladder cancer (NMIBC) at the Princess Margaret 
Cancer Center in Toronto, Canada. It is noteworthy that although several other 
Ru-based complexes (NAMI-A, KP1019, and KP1339) have currently entered clini-
cal trials as antineoplastic drugs, TLD-1433 is meanwhile the only transition metal 
complex tested in a trial as a PS for PDT [5, 53].
TLD-1433-mediated PDT (525 nm, 3 W, target dose = 90 Jcm−2) with intravesi-
cal irradiation demonstrated safety and efficacy of the PS in patients with non-mus-
cle invasive urinary bladder cancer (NMIBC) who were previously unresponsive to 
contemporary anticancer therapy, including the intravesical therapy with Bacillus 
Calmette-Guérin (BCG) [54]. At therapeutic dose (0.70 mg per cm2 of bladder 
surface), 2 of 3 patients were tumor-free at the 180-day posttreatment, with no 
essential adverse effects and minimal systemic absorption of the PS (complete 
clearance from the plasma within 72 hrs) and no photosensitivity reactions. This 
outcome is successful enough to warrant further advance to a phase II trial.
7. PS activation by ionizing radiation
It is worth noting that at least one of the PSs under discussion, TLD-1433, can 
be activated not only by nonionizing electromagnetic radiation but also by ionizing 
one (X-ray). Transition metal complexes are theoretically prone to this because the 
atoms of transitional metals can attenuate X-rays. For example, Ru attenuates X-ray 
photons at 75 keV to an extent comparable to iodine, an established X-ray imaging 
agent [55]. Activation of the PS by X-ray is very advantageous because it allows 
treatment of the tumors located considerably deeper than reachable by NIR. TLD-
1433 retains its functionality after 75 keV irradiation at doses up to 20Gy and retains 
its ability to generate postirradiation *OH signal under subsequent red light expo-
sure. In cultured human glioblastoma U87 cells, 20 μM TLD-1433 exerted non-zero 
radio-enhancement effect after 75 keV X-ray exposure (5 Gy) at the magnitude of 
37% cell kill (P = 0.020, df = 3), at dark toxicity of 20% cell kill (P = 0.009, df = 3). 
Moreover, the effect can be detected in vivo in CT26.WT tumors induced in BalbC 
mice. At 1 Gy, X-ray resulted in a 2.9-fold increase in coagulative necrosis area in 
the tumors on day 2 postexposure vs. TL1433 alone and X-ray alone groups pooled 
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(P = 0.007, df = 15) [56]. It is noteworthy that thermal effects at these conditions 
are highly unlikely because 1 Gy deposits only 0.001 J per gr tissue, which, at the 
estimated average specific heat capacity C ≈ 3.7 J g−1 K−1 [57], provides a very small 
(0.0003°C) increase in temperature.
8. Conclusions
In vitro and in vivo data suggest that transition metal-based complexes 
are versatile as PSs with diverse photophysical, photochemical, and biological 
properties. This includes activation over a wide range of wavelengths and high 
singlet oxygen yield and photobleaching resistance. The Ru(II)-based PSs may 
have very high cytotoxic efficacy far exceeding the established porphyrin-based 
PSs. The Os(II)-based PSs are notable in their PDT activity at deeper-penetrating 
NIR light PDT. Moreover, even Ru(II)-based PSs could be effective in vivo under 
NIR light. Transition metal-based PSs demonstrate both Type I and Type II 
photoreactions and can be active in hypoxic conditions, presenting the potential 
for the treatment of bulky hypoxic tumors. These properties are further facili-
tated by their ability to associate with endogenous metal transporter molecules, 
like human apo-Tf, which enables their targeted endocytosis. Furthermore, the 
association with Tf increases absorptivity at longer wavelengths (far red to NIR 
range), ROS generation, and finally tumor destroying potential. The observed 
capacities of the PSs may allow overcoming notorious challenges of PDT: the 
necessity for deeper light penetration, the selectivity of accumulation in tumors, 
and activity under hypoxic conditions. Finally, the research has led to the first 
clinical trial for this class of PSs, with a successful outcome and potential to 
further clinical advance. This raises justified hopes that with the ongoing tech-
nological improvements, such as the development of transition metal complexes 
(including the advanced Theralase PSs discussed above), and personalized 
dosimetry with a treatment planning approach, PDT has the potential to become 
integrated into the mainstream of cancer treatment.
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